|
Dana-Farber Cancer Institute is a founding member of a small national consortium of leading medical centers that investigates new treatments for children with Hodgkin's disease. Through this consortium, Dana-Farber/Children's Hospital Cancer Care (DF/CHCC) physicians are investigating new drug combinations that deliver good results with fewer long-term complications. Currently, we are accruing patients for a research study investigating treatment for low-risk and advanced Hodgkin's disease.
In addition, DF/CHCC offers access to all Children's Oncology Group's Phase I clinical trials and other trials for relapsed Hodgkin's.
If you are interested in learning about our clinical trials, visit our
online listing or contact our New Patient Coordinator at 1-888-PEDI-ONC.
|
